These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 15569985)

  • 1. Epidermal growth factor receptor tyrosine kinase inhibition represses cyclin D1 in aerodigestive tract cancers.
    Petty WJ; Dragnev KH; Memoli VA; Ma Y; Desai NB; Biddle A; Davis TH; Nugent WC; Memoli N; Hamilton M; Iwata KK; Rigas JR; Dmitrovsky E
    Clin Cancer Res; 2004 Nov; 10(22):7547-54. PubMed ID: 15569985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High cyclin D3 expression confers erlotinib resistance in aerodigestive tract cancer.
    Petty WJ; Voelzke WR; Urbanic JJ; Varela VA; Waller LL; Swift CB; Graham RM; Memoli VA; Dragnev KH
    Lung Cancer; 2011 Dec; 74(3):384-91. PubMed ID: 21555162
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bexarotene and erlotinib for aerodigestive tract cancer.
    Dragnev KH; Petty WJ; Shah S; Biddle A; Desai NB; Memoli V; Rigas JR; Dmitrovsky E
    J Clin Oncol; 2005 Dec; 23(34):8757-64. PubMed ID: 16314636
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deregulated cyclin D1 expression is associated with decreased efficacy of the selective epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in head and neck squamous cell carcinoma cell lines.
    Kalish LH; Kwong RA; Cole IE; Gallagher RM; Sutherland RL; Musgrove EA
    Clin Cancer Res; 2004 Nov; 10(22):7764-74. PubMed ID: 15570011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel targeted approaches to treating biliary tract cancer: the dual epidermal growth factor receptor and ErbB-2 tyrosine kinase inhibitor NVP-AEE788 is more efficient than the epidermal growth factor receptor inhibitors gefitinib and erlotinib.
    Wiedmann M; Feisthammel J; Blüthner T; Tannapfel A; Kamenz T; Kluge A; Mössner J; Caca K
    Anticancer Drugs; 2006 Aug; 17(7):783-95. PubMed ID: 16926628
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
    Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA
    Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A proof-of-principle clinical trial of bexarotene in patients with non-small cell lung cancer.
    Dragnev KH; Petty WJ; Shah SJ; Lewis LD; Black CC; Memoli V; Nugent WC; Hermann T; Negro-Vilar A; Rigas JR; Dmitrovsky E
    Clin Cancer Res; 2007 Mar; 13(6):1794-800. PubMed ID: 17363535
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers.
    Guix M; Granja Nde M; Meszoely I; Adkins TB; Wieman BM; Frierson KE; Sanchez V; Sanders ME; Grau AM; Mayer IA; Pestano G; Shyr Y; Muthuswamy S; Calvo B; Krontiras H; Krop IE; Kelley MC; Arteaga CL
    J Clin Oncol; 2008 Feb; 26(6):897-906. PubMed ID: 18180460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
    Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
    Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Retinoid targeting of different D-type cyclins through distinct chemopreventive mechanisms.
    Ma Y; Feng Q; Sekula D; Diehl JA; Freemantle SJ; Dmitrovsky E
    Cancer Res; 2005 Jul; 65(14):6476-83. PubMed ID: 16024653
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced sensitivity to the HER1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib hydrochloride in chemotherapy-resistant tumor cell lines.
    Dai Q; Ling YH; Lia M; Zou YY; Kroog G; Iwata KK; Perez-Soler R
    Clin Cancer Res; 2005 Feb; 11(4):1572-8. PubMed ID: 15746062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transcriptional profiling identifies cyclin D1 as a critical downstream effector of mutant epidermal growth factor receptor signaling.
    Kobayashi S; Shimamura T; Monti S; Steidl U; Hetherington CJ; Lowell AM; Golub T; Meyerson M; Tenen DG; Shapiro GI; Halmos B
    Cancer Res; 2006 Dec; 66(23):11389-98. PubMed ID: 17145885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients.
    Yauch RL; Januario T; Eberhard DA; Cavet G; Zhu W; Fu L; Pham TQ; Soriano R; Stinson J; Seshagiri S; Modrusan Z; Lin CY; O'Neill V; Amler LC
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8686-98. PubMed ID: 16361555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The anti-proliferative effect of heat shock protein 90 inhibitor, 17-DMAG, on non-small-cell lung cancers being resistant to EGFR tyrosine kinase inhibitor.
    Kobayashi N; Toyooka S; Soh J; Yamamoto H; Dote H; Kawasaki K; Otani H; Kubo T; Jida M; Ueno T; Ando M; Ogino A; Kiura K; Miyoshi S
    Lung Cancer; 2012 Feb; 75(2):161-6. PubMed ID: 21767894
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of MET activation in determining the sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors.
    Rho JK; Choi YJ; Lee JK; Ryoo BY; Na II; Yang SH; Lee SS; Kim CH; Yoo YD; Lee JC
    Mol Cancer Res; 2009 Oct; 7(10):1736-43. PubMed ID: 19808904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HER2 overexpression increases sensitivity to gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, through inhibition of HER2/HER3 heterodimer formation in lung cancer cells.
    Hirata A; Hosoi F; Miyagawa M; Ueda S; Naito S; Fujii T; Kuwano M; Ono M
    Cancer Res; 2005 May; 65(10):4253-60. PubMed ID: 15899817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Posttranslational mechanisms contribute to the suppression of specific cyclin:CDK complexes by all-trans retinoic acid in human bronchial epithelial cells.
    Sueoka N; Lee HY; Walsh GL; Hong WK; Kurie JM
    Cancer Res; 1999 Aug; 59(15):3838-44. PubMed ID: 10447003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of biologic end points and pharmacokinetics in patients with metastatic breast cancer after treatment with erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor.
    Tan AR; Yang X; Hewitt SM; Berman A; Lepper ER; Sparreboom A; Parr AL; Figg WD; Chow C; Steinberg SM; Bacharach SL; Whatley M; Carrasquillo JA; Brahim JS; Ettenberg SA; Lipkowitz S; Swain SM
    J Clin Oncol; 2004 Aug; 22(15):3080-90. PubMed ID: 15284258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
    Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
    Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva).
    Chinnaiyan P; Huang S; Vallabhaneni G; Armstrong E; Varambally S; Tomlins SA; Chinnaiyan AM; Harari PM
    Cancer Res; 2005 Apr; 65(8):3328-35. PubMed ID: 15833866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.